Business Context and Reporting Period
This Form 8-K is filed by Neuralstem, Inc. (not Palisade Bio, Inc., as indicated in the metadata) on November 30, 2018, reporting an event that occurred on November 29, 2018. The filing addresses a regulatory compliance issue regarding the company's listing status on the Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the stock's closing bid price, which has fallen below the $1.00 per share threshold required by Nasdaq Listing Rule 5550(a)(2) over the last 30 consecutive business days.
Material Changes
The material change reported is the receipt of a formal notice from Nasdaq indicating non-compliance with the Minimum Bid Price requirement. This notice initiates a compliance period but has no immediate effect on the listing of the company's common stock.
Outlook, Risks, and Management Commentary
- Compliance Timeline: The company has been granted 180 calendar days, until May 28, 2019, to regain compliance.
- Remediation Path: Compliance can be achieved if the bid price closes at or above $1.00 per share for a minimum of ten consecutive business days during the initial period.
- Secondary Compliance Period: If the initial deadline is missed, the company may qualify for an additional 180-day period if it meets all other initial listing standards (excluding bid price) and intends to cure the deficiency, potentially via a reverse stock split.
- Risk of Delisting: Failure to cure the deficiency or meet eligibility requirements for the second period may result in delisting. The company retains the right to appeal a delisting determination to a Hearings Panel.
- Management Action: Management intends to actively monitor the bid price and consider available options to resolve the deficiency.
Investor Verification Checklist
- Verify the current trading price of Neuralstem, Inc. common stock to assess proximity to the $1.00 threshold.
- Monitor future filings for announcements regarding a reverse stock split or other capital structure changes.
- Check for any subsequent correspondence from Nasdaq regarding the status of the compliance period.
- Review the company's most recent 10-K or 10-Q for liquidity and cash runway, as this 8-K does not contain financial statements.